This phase III trial is combining BRAF and EGFR inhibitiors in the treatment of BRAF V600E mutant colorectal, advanced or metastatic lung cancer.
This trial is treating multiple types of cancer including Colorectal, Small Cell Lung Cancer, Non Small Cell Lung Cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment, but your cancer has come back.
- Your cancer has spread to other parts of the body.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have had certain treatments, surgical procedures or drugs.
- You have a certain disease or psychological condition.
- You have previously been treated (or are currently being treated) on a clinical trial.
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I/II Trial of the combination of BRAF and EGFR inhibition in BRAF V600E mutant colorectal, advanced or metastatic lung adenocarcinoma and other cancers.
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
The aim of the study is to assess the safety and efficacy of chemotherapy treatment with a combination of erlotinib and vemurafenib in patients with BRAF V600E mutant colorectal and non-small lung cancer.
Who is it for?
You may be eligible to join this study if you aged 18 years or more and have a confirmed diagnosis of metastatic colorectal cancer or non-small cell lung cancer with a BRAF V600E mutation of your primary cancer or related metastases.
There are two parts to this study. In the first part, participants with metastatic colorectal cancer will be treated with erlotinib and vemurafenib daily until disease progression or unacceptable toxicities. Both of these chemotherapy drugs are administered in tablet form and taken orally. The dose administered will be increased in subsequent patient groups in order to determine the maximum tolerated dose to be used in the second part of the study.
Patients with metastatic colorectal cancer or non-small cell lung cancer are eligible for the second part of the study. They will also be treated with oral erlotinib and vemurafenib daily until disease progression or unacceptable toxicities.
All participants will be regularly monitored and assessed for a period of up to 18 months in order to evaluate the safety and efficacy of treatment.
Recruiting Hospitals Read More